Base de dados : MEDLINE
Pesquisa : D03.383.129.308.704 [Categoria DeCS]
Referências encontradas : 607 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 61 ir para página                         

  1 / 607 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28837365
[Au] Autor:Patel NU; Shukla S; Zaki J; Feldman SR
[Ad] Endereço:a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
[Ti] Título:Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
[So] Source:Expert Rev Clin Pharmacol;10(10):1049-1054, 2017 Oct.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face. The symptom of persistent erythema can be particularly frustrating for both patients and physicians as it is difficult to treat. Areas covered: Current treatment options for the treatment of rosacea include metronidazole, azelaic acid, sodium sulfacetamide-sulfur, and brimonidine. Until recently, brimonidine gel was the only option approved specifically for the treatment of facial erythema. However, oxymetazoline hydrochloride 1% cream is a newly FDA approved topical medication for adult rosacea patients. A primarily alpha-1a agonist, oxymetazoline hydrochloride (HCl) is thought to diminish erythema through vasoconstriction. Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea. Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice. As further evidence becomes available, the real-world clinical potential of topical oxymetazoline cream will become clearer.
[Mh] Termos MeSH primário: Eritema/tratamento farmacológico
Oximetazolina/administração & dosagem
Rosácea/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Agonistas alfa-Adrenérgicos/administração & dosagem
Agonistas alfa-Adrenérgicos/efeitos adversos
Agonistas alfa-Adrenérgicos/farmacologia
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Fármacos Dermatológicos/farmacologia
Eritema/etiologia
Eritema/patologia
Seres Humanos
Oximetazolina/efeitos adversos
Oximetazolina/farmacologia
Rosácea/patologia
Creme para a Pele
Vasoconstrição/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-Agonists); 0 (Dermatologic Agents); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1370370


  2 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28160292
[Au] Autor:Schechtman SA; Wertz AP; Shanks A; Thompson A; Tremper K; Pynnonen MA; Healy DW
[Ad] Endereço:Department of Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, U.S.A.
[Ti] Título:Preoperative ß-blockade and hypertension in the first hour of functional endoscopic sinus surgery.
[So] Source:Laryngoscope;127(7):1496-1505, 2017 Jul.
[Is] ISSN:1531-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES/HYPOTHESIS: Local anesthetic with epinephrine is commonly injected into the nasal mucosa during functional endoscopic sinus surgery (FESS). Systemic absorption of epinephrine following local injection may occur, resulting in a mild sympathetic response. This study seeks to determine whether an exaggerated sympathetic response to epinephrine is demonstrated in patients undergoing FESS treated preoperatively with established pharmacologic beta (ß) adrenoceptor blockade. STUDY DESIGN: A retrospective analysis of adult patients undergoing FESS at a tertiary care university hospital. METHODS: The primary outcome was the occurrence of an exaggerated hypertensive response within the first hour of surgical time defined by a relative increase (>20%) in the first measured intraoperative systolic blood pressure (SBP) prior to induction of anesthesia, or a single SBP value above 200 mm Hg. A mixed effects logistic regression model was developed to identify independent predictors of an exaggerated hypertensive response and describe the variance in the outcome attributable to the surgeon and anesthesiologist. RESULTS: There were 2,051 patients identified. Independent predictors of an exaggerated intraoperative hypertensive event included: preoperative ß-blocker use (adjusted odds ratio [AOR]: 3.33), female gender (AOR: 1.92), body mass index (AOR: 1.03), lower baseline SBP (AOR: 0.93), and advanced age (AOR: 1.03). The C statistic for the model was 0.8881. CONCLUSIONS: Preoperative ß-blocker use is an independent predictor of an exaggerated hypertensive response within the first hour of operative time. An exaggerated hypertensive effect should be anticipated in patients presenting for FESS with established pharmacologic ß-blockade, and caution should be applied to use of epinephrine-containing solutions. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1496-1505, 2017.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Antagonistas Adrenérgicos beta/efeitos adversos
Anestésicos Locais/administração & dosagem
Anestésicos Locais/efeitos adversos
Epinefrina/administração & dosagem
Epinefrina/efeitos adversos
Hipertensão/induzido quimicamente
Complicações Intraoperatórias/induzido quimicamente
Cuidados Pré-Operatórios
Sinusite/cirurgia
Sistema Nervoso Simpático/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Doença Crônica
Interações Medicamentosas
Feminino
Seres Humanos
Injeções
Lidocaína
Masculino
Meia-Idade
Mucosa Nasal/efeitos dos fármacos
Oximetazolina/administração & dosagem
Oximetazolina/efeitos adversos
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Anesthetics, Local); 8VLN5B44ZY (Oxymetazoline); 98PI200987 (Lidocaine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170205
[St] Status:MEDLINE
[do] DOI:10.1002/lary.26492


  3 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27621136
[Au] Autor:Fathy ME; Abo El Abass Mohamed S; Elmansi H; Belal F
[Ad] Endereço:Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, 35516 Mansoura, Egypt.
[Ti] Título:Simultaneous Determination of Cromolyn Sodium Combined Dosage Forms Using Isocratic HPLC Method.
[So] Source:J Chromatogr Sci;55(1):14-22, 2017 01.
[Is] ISSN:1945-239X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A simple and selective reversed-phase high-performance liquid chromatography method was developed for the estimation of cromolyn sodium (CRM) with either oxymetazoline hydrochloride (OMZ) or xylometazoline hydrochloride (XMZ) in their binary mixtures. The method is based on the simultaneous separation of each drug in a reversed-phase Waters symmetry C18 column (250 mm × 4.6 mm intradermally, 5-µm particle size) at 25°C. Elution was performed with a mobile phase consisting of methanol : 0.1 M phosphate buffer (60:40, v/v, pH 4.0). Quantitation was achieved with ultraviolet detection at 220 nm. The method could determine the three drugs, with linearity, in the range of 2.0-100.0 µg/mL for CRM and 0.8-8.0 µg/mL for OMZ and for XMZ. Aspirin was used as internal standard. Optimization of the separation in terms of mobile phase composition is critical to the method development, which is discussed in detail. The suggested procedure was successfully applied to the analysis of the studied drugs in their nasal preparations. Statistical evaluation of the data obtained by the proposed and comparison methods revealed good accuracy of the proposed method.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Cromolina Sódica/análise
[Mh] Termos MeSH secundário: Cromolina Sódica/química
Combinação de Medicamentos
Imidazóis/análise
Imidazóis/química
Limite de Detecção
Modelos Lineares
Oximetazolina/análise
Oximetazolina/química
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Imidazoles); 8VLN5B44ZY (Oxymetazoline); Q2WXR1I0PK (Cromolyn Sodium); WPY40FTH8K (xylometazoline)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160914
[St] Status:MEDLINE


  4 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27436060
[Au] Autor:Cacek AT; Gobburu JV; Gopalakrishnan M
[Ad] Endereço:ContractKinetica, Columbia, MO, USA.
[Ti] Título:Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers.
[So] Source:J Clin Pharmacol;57(2):247-254, 2017 Feb.
[Is] ISSN:1552-4604
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The primary objective of the current investigation was to establish the pharmacokinetic characteristics of oxymetazoline and tetracaine's primary metabolite, para-butylaminobenzoic acid (PBBA), after the intranasal administration of oxymetazoline/tetracaine. Thirty-six subjects contributing a total of 1791 plasma concentration results from 2 open-label trials were utilized. Model development was achieved using data from the second trial (N = 24) in which 0.3 mg oxymetazoline/18 mg tetracaine was administered. External model validation utilized data from the first trial (N = 12), which included doses of 0.3 mg oxymetazoline/18 mg tetracaine and 0.6 mg oxymetazoline/36 mg tetracaine. Oxymetazoline and PBBA dispositions were described by a 2-compartment model with first-order absorption. An allometric model for body weight was included on volumes and clearances to describe unexplained between-subject variability. The final oxymetazoline parameter estimates were k 4.41 h ; peripheral volume 418 L; clearance 66.4 L/h; central volume 6.97 L; and intercompartmental clearance 419 L/h for a 70-kg subject. The final PBBA parameter estimates were k 8.51 h ; peripheral volume 32.0 L; clearance 16.7 L/h; central volume 29.8 L; and intercompartmental clearance 2.43 L/h for a 70-kg subject. Between-subject variability ranged from 14% to 39% for oxymetazoline and from 10% to 94% for PBBA.
[Mh] Termos MeSH primário: Anestésicos Locais/farmacocinética
Descongestionantes Nasais/farmacocinética
Oximetazolina/farmacocinética
Tetracaína/farmacocinética
[Mh] Termos MeSH secundário: Administração Intranasal
Adulto
Algoritmos
Anestésicos Locais/administração & dosagem
Biotransformação
Combinação de Medicamentos
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
Descongestionantes Nasais/administração & dosagem
Sprays Nasais
Oximetazolina/administração & dosagem
População
Tetracaína/administração & dosagem
Adulto Jovem
para-Aminobenzoatos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (Drug Combinations); 0 (Nasal Decongestants); 0 (Nasal Sprays); 0 (para-Aminobenzoates); 0619F35CGV (Tetracaine); 4740-24-3 (4-n-butylaminobenzoic acid); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160721
[St] Status:MEDLINE
[do] DOI:10.1002/jcph.799


  5 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27748955
[Au] Autor:Deckx L; De Sutter AI; Guo L; Mir NA; van Driel ML
[Ad] Endereço:Discipline of General Practice, School of Medicine, The University of Queensland, Building 16/910, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia, 4029.
[Ti] Título:Nasal decongestants in monotherapy for the common cold.
[So] Source:Cochrane Database Syst Rev;10:CD009612, 2016 Oct 17.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Many treatments for the common cold exist and are sold over-the-counter. Nevertheless, evidence on the effectiveness and safety of nasal decongestants is limited. OBJECTIVES: To assess the efficacy, and short- and long-term safety, of nasal decongestants used in monotherapy to alleviate symptoms of the common cold in adults and children. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6, June 2016), which contains the Cochrane Acute Respiratory Infections (ARI) Specialised Register, MEDLINE (1946 to July 2016), Embase (2010 to 15 July 2016), CINAHL (1981 to 15 July 2016), LILACS (1982 to July 2016), Web of Science (1955 to July 2016) and clinical trials registers. SELECTION CRITERIA: Randomised controlled trials (RCTs) and cluster-RCTs investigating the effectiveness and adverse effects of nasal decongestants compared with placebo for treating the common cold in adults and children. We excluded quasi-RCTs. DATA COLLECTION AND ANALYSIS: Three review authors independently extracted and summarised data on subjective measures of nasal congestion, overall patient well-being score, objective measures of nasal airway resistance, adverse effects and general recovery. One review author acted as arbiter in cases of disagreement. We categorised trials as single and multi-dose and analysed data both separately and together. We also analysed studies using an oral or topical nasal decongestant separately and together. MAIN RESULTS: We included 15 trials with 1838 participants. Fourteen studies included adult participants only (aged 18 years and over). In six studies the intervention was a single dose and in nine studies multiple doses were used. Nine studies used pseudoephedrine and three studies used oxymetazoline. Other decongestants included phenylpropanolamine, norephedrine and xylometazoline. Phenylpropanolamine (or norephedrine) is no longer available on the market therefore we did not include the results of these studies in the meta-analyses. Eleven studies used oral decongestants; four studies used topical decongestants.Participants were included after contracting the common cold. The duration of symptoms differed among studies; in 10 studies participants had symptoms for less than three days, in three studies symptoms were present for less than five days, one study counted the number of colds over one year, and one study experimentally induced the common cold. In the single-dose studies, the effectiveness of a nasal decongestant was measured on the same day, whereas the follow-up in multi-dose studies ranged between one and 10 days.Most studies were conducted in university settings (N = eight), six at a specific university common cold centre. Three studies were conducted at a university in collaboration with a hospital and two in a hospital only setting. In two studies the setting was unclear.There were large differences in the reporting of outcomes and the reporting of methods in most studies was limited. Therefore, we judged most studies to be at low or unclear risk of bias. Pooling was possible for a limited number of studies only; measures of effect are expressed as standardised mean differences (SMDs). A positive SMD represents an improvement in congestion. There is no defined minimal clinically important difference for measures of subjective improvement in nasal congestion, therefore we used the SMDs as a guide to assess whether an effect was small (0.2 to 0.49), moderate (0.5 to 0.79) or large (≥ 0.8).Single-dose decongestant versus placebo: 10 studies compared a single dose of nasal decongestant with placebo and their effectiveness was tested between 15 minutes and 10 hours after dosing. Seven of 10 studies reported subjective symptom scores for nasal congestion; none reported overall patient well-being. However, pooling was not possible due to the large diversity in the measurement and reporting of symptoms of congestion. Two studies recorded adverse events. Both studies used an oral decongestant and each of them showed that there was no statistical difference between the number of adverse events in the treatment group versus the placebo group.Multi-dose decongestant versus placebo: nine studies compared multiple doses of nasal decongestants with placebo, but only five reported on the primary outcome, subjective symptom scores for nasal congestion. Only one study used a topical decongestant; none reported overall patient well-being. Subjective measures of congestion were significantly better for the treatment group compared with placebo approximately three hours after the last dose (SMD 0.49, 95% confidence interval (CI) 0.07 to 0.92; P = 0.02; GRADE: low-quality evidence). However, the SMD of 0.49 only indicates a small clinical effect. Pooling was based on two studies, one oral and one topical, therefore we were unable to assess the effects of oral and topical decongestants separately. Seven studies reported adverse events (six oral and one topical decongestant); meta-analysis showed that there was no statistical difference between the number of adverse events in the treatment group (125 per 1000) compared to the placebo group (126 per 1000). The odds ratio (OR) for adverse events in the treatment group was 0.98 (95% CI 0.68 to 1.40; P = 0.90; GRADE: low-quality evidence). The results remained the same when we only considered studies using an oral decongestant (OR 0.95, 95% CI 0.65 to 1.39; P = 0.80; GRADE: low-quality evidence). AUTHORS' CONCLUSIONS: We were unable to draw conclusions on the effectiveness of single-dose nasal decongestants due to the limited evidence available. For multiple doses of nasal decongestants, the current evidence suggests that these may have a small positive effect on subjective measures of nasal congestion in adults with the common cold. However, the clinical relevance of this small effect is unknown and there is insufficient good-quality evidence to draw any firm conclusions. Due to the small number of studies that used a topical nasal decongestant, we were also unable to draw conclusions on the effectiveness of oral versus topical decongestants. Nasal decongestants do not seem to increase the risk of adverse events in adults in the short term. The effectiveness and safety of nasal decongestants in children and the clinical relevance of their small effect in adults is yet to be determined.
[Mh] Termos MeSH primário: Resfriado Comum/tratamento farmacológico
Descongestionantes Nasais/administração & dosagem
[Mh] Termos MeSH secundário: Administração Intranasal
Adulto
Criança
Seres Humanos
Imidazóis/administração & dosagem
Descongestionantes Nasais/efeitos adversos
Oximetazolina/administração & dosagem
Fenilpropanolamina/administração & dosagem
Pseudoefedrina/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Imidazoles); 0 (Nasal Decongestants); 33RU150WUN (Phenylpropanolamine); 7CUC9DDI9F (Pseudoephedrine); 8VLN5B44ZY (Oxymetazoline); WPY40FTH8K (xylometazoline)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161102
[St] Status:MEDLINE


  6 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27687457
[Au] Autor:Abrons RO; Vansickle RA; Ouanes JP
[Ad] Endereço:Department of Anesthesiology, University of Iowa Hospitals and Clinics, Iowa City, IA.
[Ti] Título:Seldinger technique for nasal intubation: a case series.
[So] Source:J Clin Anesth;34:609-11, 2016 Nov.
[Is] ISSN:1873-4529
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nasotracheal intubation can be both challenging and traumatic, especially in cases of atypical anatomy. We present a series of 3 such cases in which an endotracheal tube introducer (bougie) was used to facilitate successful, atraumatic, nasotracheal intubation via Seldinger technique. The technique described can guide a nasotracheal tube through narrow nasal passages, small pharyngeal spaces, and past acute laryngeal approach angles, all without transoral manipulation of the tube. The technique is easy to perform, uses a routine skill set, and can be advantageous in numerous clinical scenarios.
[Mh] Termos MeSH primário: Glossectomia/efeitos adversos
Intubação Intratraqueal/métodos
Hemorragia Pós-Operatória/etiologia
Língua/cirurgia
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Anestesia Geral
Anestésicos Locais/administração & dosagem
Pré-Escolar
Seres Humanos
Intubação Intratraqueal/instrumentação
Laringoscópios
Lidocaína/administração & dosagem
Lubrificantes/administração & dosagem
Masculino
Meia-Idade
Cavidade Nasal/efeitos dos fármacos
Descongestionantes Nasais/administração & dosagem
Mucosa Nasal/efeitos dos fármacos
Oximetazolina/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (Lubricants); 0 (Nasal Decongestants); 8VLN5B44ZY (Oxymetazoline); 98PI200987 (Lidocaine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161001
[St] Status:MEDLINE


  7 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27216350
[Au] Autor:Kirtsreesakul V; Khanuengkitkong T; Ruttanaphol S
[Ad] Endereço:Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
[Ti] Título:Does oxymetazoline increase the efficacy of nasal steroids in treating nasal polyposis?
[So] Source:Am J Rhinol Allergy;30(3):195-200, 2016 May.
[Is] ISSN:1945-8932
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although nasal steroids are the mainstay treatments in nasal polyposis, up to one-half of patients do not respond and need surgical treatment. This study aimed to evaluate whether oxymetazoline administration produces any additive effect on nasal steroid therapy and whether rebound congestion develops after oxymetazoline treatment. METHODS: Sixty-eight patients with nasal polyposis were randomly assigned in a 1:1 ratio to receive either oxymetazoline plus mometasone furoate nasal spray (MFNS) or placebo plus MFNS, 2 sprays per nostril twice daily, with an interval of 5 minutes between each medication for 4 weeks. All the patients were then treated with MFNS, 2 sprays per nostril twice daily for 2 weeks. The nasal symptoms score, peak inspiratory flow index, nasal mucociliary clearance time (NMCCT), and total nasal polyps score were used to evaluate treatment outcomes. An intention-to-treat analysis was performed, and a worst case sensitivity analysis was applied to missing cases. RESULTS: Thirty-four patients were allocated to the oxymetazoline-MFNS group, and 34 to the placebo-MFNS group. One patient in each group was lost to last-visit follow-up. At 4 weeks after beginning treatment, the oxymetazoline-MFNS group showed significantly greater improvement in blocked nose, hyposmia, peak flow, NMCCT, and total nasal polyps score than the placebo-MFNS group. During the nasal steroid phase, both groups showed continuing improvement in all outcome variables. However, the oxymetazoline-MFNS group still showed significantly greater improvement in blocked nose, hyposmia, NMCCT, and total nasal polyps score, but not peak flow, than the placebo-MFNS group at the end of the study. CONCLUSION: The use of nasal steroids with oxymetazoline was more effective over 6 weeks than nasal steroids alone in improving blocked nose, hyposmia, nasal mucociliary clearance, and polyp size in treatment of nasal polyposis. There was no evidence of rebound congestion after 4 weeks of oxymetazoline treatment.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Furoato de Mometasona/uso terapêutico
Pólipos Nasais/tratamento farmacológico
Oximetazolina/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intranasal
Adolescente
Adulto
Idoso
Sinergismo Farmacológico
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Anti-Inflammatory Agents); 04201GDN4R (Mometasone Furoate); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160525
[St] Status:MEDLINE
[do] DOI:10.2500/ajra.2016.30.4294


  8 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27156558
[Au] Autor:Gopalakrishnan S; Sodhi K
[Ad] Endereço:Department of Pediatrics, Command Hospital (Western Command), Panchkula, Haryana, India. shri27cat@gmail.com.
[Ti] Título:Recurrent Apnea in a Neonate Following Intranasal Oxymetazoline.
[So] Source:Indian Pediatr;53(4):353, 2016 Apr.
[Is] ISSN:0974-7559
[Cp] País de publicação:India
[La] Idioma:eng
[Mh] Termos MeSH primário: Apneia/etiologia
Oximetazolina/efeitos adversos
Simpatomiméticos/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Masculino
Oximetazolina/administração & dosagem
Oximetazolina/uso terapêutico
Estudos Retrospectivos
Simpatomiméticos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sympathomimetics); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160510
[St] Status:MEDLINE


  9 / 607 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27087030
[Au] Autor:Menezes GA; Araujo Júnior E; Lopes J; Belmonte S; Tonni G; Werner H
[Ad] Endereço:Department of Gynecology and Obstetrics, Federal University of Latin American Integration (UNILA), Foz do Iguacu, Brazil.
[Ti] Título:Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester.
[So] Source:J Obstet Gynaecol Res;42(8):1016-20, 2016 Aug.
[Is] ISSN:1447-0756
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Agnathia-otocephaly or agnathia-sinotia-microstomy syndrome is the most severe malformation affecting the first branchial arch. It is a rare congenital anomaly characterized by absence of the lower jaw and abnormal ear positioning. Prenatal diagnosis is possible on conventional 2-D ultrasound in the second trimester. Three-dimensional ultrasound enhances detection of abnormal facial phenotype, especially in surface rendering mode. In addition, 3-D volume datasets are used to produce a physical model of the anomaly. We present a case of second trimester ultrasound diagnosis of agnathia-otocephaly associated with limb deformities. A physical model produced using 3-D ultrasound volume datasets facilitated better understanding of this congenital malformation, and improvement of parental counselling and management by the multispecialist team.
[Mh] Termos MeSH primário: Anormalidades Craniofaciais/diagnóstico por imagem
Exposição Materna
Descongestionantes Nasais/efeitos adversos
Oximetazolina/efeitos adversos
Ultrassonografia Pré-Natal/métodos
[Mh] Termos MeSH secundário: Adulto
Região Branquial/anormalidades
Região Branquial/diagnóstico por imagem
Feminino
Fíbula/anormalidades
Fíbula/diagnóstico por imagem
Dedos/anormalidades
Dedos/diagnóstico por imagem
Seres Humanos
Interpretação de Imagem Assistida por Computador
Imagem Tridimensional/métodos
Gravidez
Primeiro Trimestre da Gravidez/efeitos dos fármacos
Segundo Trimestre da Gravidez
Ulna/anormalidades
Ulna/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Nasal Decongestants); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160419
[St] Status:MEDLINE
[do] DOI:10.1111/jog.13014


  10 / 607 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27055717
[Au] Autor:Barone DA; Krieger AC
[Ad] Endereço:Weill Cornell Medical College of Cornell University, New York, NY. Electronic address: dab9129@med.cornell.edu.
[Ti] Título:A 45-Year-Old Man With Delayed Onset of OSA Events During Polysomnography.
[So] Source:Chest;149(4):e123-6, 2016 Apr.
[Is] ISSN:1931-3543
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 45-year-old man with a medical history that included asthma and chronic nasal congestion presented for an evaluation of possible OSA. He reported loud snoring, witnessed apneas in sleep, and daytime sleepiness. The patient's score on the Epworth Sleepiness Scale was 12 of 24, indicating excessive sleepiness. His nasal congestion had been treated with frequent use of an over-the-counter nasal decongestant.
[Mh] Termos MeSH primário: Descongestionantes Nasais/efeitos adversos
Oximetazolina/efeitos adversos
Polissonografia
Rinite Alérgica/tratamento farmacológico
Apneia Obstrutiva do Sono/induzido quimicamente
Síndrome de Abstinência a Substâncias/etiologia
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
Apneia Obstrutiva do Sono/diagnóstico
Apneia Obstrutiva do Sono/fisiopatologia
Síndrome de Abstinência a Substâncias/diagnóstico
Síndrome de Abstinência a Substâncias/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nasal Decongestants); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160408
[Lr] Data última revisão:
160408
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160409
[St] Status:MEDLINE



página 1 de 61 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde